PROTEIN-BASED PLATFORM TO GENERATE CHIMERIC ANTIGEN RECEPTOR-IMMUNE CELLS

Antigen specific T cells and Natural Killer (NK) cells generated by virus- mediated gene transfer of Chimeric Antigen Receptors (CAR) has drastically advanced cancer immunotherapy. However, virus-mediated redirection typically results in permanent CAR gene expression and off- tumor toxicity. The recombinant CAR fusion protein (rCAR) developed is mixed with isolated T and NK cells in vitro, resulting in temporarily activated cells ready for infusion in a matter of hours, rather than days or weeks from traditional methodologies. The rCAR technology is a promising advancement for treating solid and hematological malignancies.